INMBINmune Bio, Inc.

$35M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000-76.7% YoY

Gross Profit

$38,000100.0% margin

Operating Income

-$6M-16902.6% margin

Net Income

-$7M-17200.0% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

-60.8%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$74M

Total Liabilities

$19M

Stockholders' Equity

$55M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$163,000	-76.7%
Gross Profit	$38,000	$163,000	-76.7%
Operating Income	-$6M	-$6M	+0.8%
Net Income	-$7M	-$7M	+5.3%

INMB Q1 2023 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena